Biotechnologically-derived Pharmaceuticals in Japan: Present and future prospects
1. The important differences between biotechnology products and conventional pharmaceuticals mean that the unthinking or routine application of standard safety tests could result in the release of biotechnologically-derived pharmaceuticals for clinical trials without adequate warning of possible adverse effects in humans.
KeywordsTransgenic Mouse Calcitonin Human Biotechnology Product Haemopoietic Factor Growth Transgenic Murine Model
Unable to display preview. Download preview PDF.
- ICH (1996). Pre-clinical Safety Tests: Safety Testing of Biotechnological Products. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. May 1 1996.Google Scholar
- Inoue T (1996). Promotion of further safety research on biotechnology products. In D’Arcy PG and Harron DWG (eds.) Proceedings of the Third International Conference on Harmonisation, Yokohama 1995. The Queens University of Belfast, Belfast, p. 238.Google Scholar
- MHW (1988). Guidelines for preparation of data required on application for approval of drugs manufactured by application of cell culture techniques. MHW Notification No 10, June 6, 1988.Google Scholar
- Nishijima I, Nakahata T, Hirabayashi Y et al. (1997). A human GM-CSF receptor expressed in transgenic mice stimulates proliferation and differentiation of hemopoietic progenitors to all lineages in response to human GM-CSF. Molecular and Cellular Biology, 6: 497–508Google Scholar
- Sporn MS and Roberts AB (eds) (1991). Peptide Growth Factors and Their Receptors. Vols. I and II. Springer-Verlag, Heidelberg & New York, pp. 1–794 and pp. 1-727.Google Scholar